دورية أكاديمية
Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma.
| العنوان: | Metformin Use and Outcome of Sunitinib Treatment in Patients With Diabetes and Metastatic Renal Cell Carcinoma. |
|---|---|
| المؤلفون: | Keizman D; Department of Oncology, Meir Medical Center, Kfar Saba, Israel. Electronic address: danielkeizman@gmail.com., Ish-Shalom M; Department of Oncology, Meir Medical Center, Kfar Saba, Israel., Sella A; Department of Oncology, Asaf Harofe Medical Center, Zerifin, Israel., Gottfried M; Department of Oncology, Meir Medical Center, Kfar Saba, Israel., Maimon N; Department of Oncology, Meir Medical Center, Kfar Saba, Israel., Peer A; Department of Oncology, Rambam Medical Center, Haifa, Israel., Hammers H; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD., Eisenberger MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD., Sinibaldi V; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD., Neiman V; Department of Oncology, Rabin Medical Center, Petach-Tikva, Israel., Rosenbaum E; Department of Oncology, Rabin Medical Center, Petach-Tikva, Israel., Sarid D; Department of Oncology, Tel Aviv Sourasky Medical center, Tel Aviv, Israel., Mermershtain W; Department of Oncology, Soroka Medical Center, Beer-Sheva, Israel., Rouvinov K; Department of Oncology, Soroka Medical Center, Beer-Sheva, Israel., Berger R; Department of Oncology, Sheba Medical Center, Tel Hashomer, Israel., Carducci MA; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD. |
| المصدر: | Clinical genitourinary cancer [Clin Genitourin Cancer] 2016 Oct; Vol. 14 (5), pp. 420-425. Date of Electronic Publication: 2016 Apr 27. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Country of Publication: United States NLM ID: 101260955 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1938-0682 (Electronic) Linking ISSN: 15587673 NLM ISO Abbreviation: Clin Genitourin Cancer Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: <2009-> : [New York] : Elsevier Original Publication: Dallas, Tex. : Cancer Information Group, c2005- |
| مواضيع طبية MeSH: | Carcinoma, Renal Cell/*drug therapy , Diabetes Mellitus/*drug therapy , Indoles/*administration & dosage , Kidney Neoplasms/*drug therapy , Metformin/*administration & dosage , Pyrroles/*administration & dosage, Aged ; Aged, 80 and over ; Comorbidity ; Disease-Free Survival ; Female ; Humans ; Indoles/therapeutic use ; Male ; Metformin/therapeutic use ; Middle Aged ; Neoplasm Metastasis ; Proportional Hazards Models ; Pyrroles/therapeutic use ; Retrospective Studies ; Sunitinib ; Treatment Outcome |
| مستخلص: | Background: Although studies in several cancer types suggest that metformin has antitumor activity, its effect on the outcome of targeted therapies in metastatic renal cell carcinoma (mRCC) is poorly defined. We aimed to analyze the effect of metformin use on the outcome of sunitinib treatment in diabetic patients with mRCC. Patients and Methods: We performed a retrospective study of diabetic patients with mRCC, who were treated with sunitinib in 8 centers across 2 countries. Patients were divided into metformin users and nonusers. The effect of metformin use on response rate, progression-free survival (PFS), and overall survival (OS), was tested. Furthermore, univariate and multivariate analyses of the association between clinicopathologic factors and metformin use, and outcome were performed using the entire patient cohort. Results: Between 2004 and 2014, 108 diabetic patients with mRCC were treated with sunitinib. There were 52 metformin users (group 1) and 56 nonusers (group 2). The groups were balanced regarding clinicopathologic factors. Clinical benefit (partial response + stable disease) in group 1 versus 2 was 96% versus 84% (P = .054). Median PFS was 15 versus 11.5 months (P = .1). Median OS was 32 versus 21 months (P = .001). In multivariate analyses of the entire patient cohort (n = 108), factors associated with PFS were active smoking and pretreatment neutrophil to lymphocyte ratio > 3. Factors associated with OS were metformin use (hazard ratio, 0.21; P < .0001), Heng risk, active smoking, liver metastases, and pretreatment neutrophil to lymphocyte ratio > 3. Conclusion: Metformin might improve the OS of diabetic patients with mRCC who are treated with sunitinib. (Copyright © 2016 Elsevier Inc. All rights reserved.) |
| فهرسة مساهمة: | Keywords: Metastatic Renal Cell Carcinoma; Metformin; Outcome; Sunitinib |
| المشرفين على المادة: | 0 (Indoles) 0 (Pyrroles) 9100L32L2N (Metformin) V99T50803M (Sunitinib) |
| تواريخ الأحداث: | Date Created: 20160524 Date Completed: 20171016 Latest Revision: 20181202 |
| رمز التحديث: | 20221213 |
| DOI: | 10.1016/j.clgc.2016.04.012 |
| PMID: | 27211307 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1938-0682 |
|---|---|
| DOI: | 10.1016/j.clgc.2016.04.012 |